Related to While Grateful for Recovery Act Funds, Experts Stress the Importance of Continued Robust Funding

• Point of View: A Golden Opportunity Choked by Red Tape
  
• Point of View: NIH Pharma Co. Is a Bad Idea
  
• Point of View: Watson, the PTO Needs You
  
• Point of View: Drug R&D Costs Questioned
  
• Legal Affairs: HHS Puts Stamp on Personalized Medicine
  
• Feature Articles: Draft Guidance for RUO Products Issued
  
• Feature Articles: Engineering Regenerative Medicine's Future
  
• Point of View: FDA Thumps Industry, Patients Feel the Pain
  
• Insight & Intelligence™: Retooling SBIR Not That Easy
  
• Wall Street BioBeat: Biotech Takes Hit from Jittery Market in Q3
  
• Feature Articles: Tips on Expertly Navigating the Biosimilar Terrain
  
• Point of View: Ownership or Stewardship?
  
• Legal Affairs: FDA Catches Up with Health IT Revolution
  
• Point of View: How Is the FDA Really Doing?
  
• Feature Articles: Bioinstrument Manufacturers Go Global
  
• Point of View: Winning the Future with Women & Girls
  
• Insight & Intelligence™: Panel Wrestles with WGS Ethics
  
• Point of View: Talking about H5N1 Research
  
• Feature Articles: Policy Makers Seek to Fortify Superbug Research
  
• Point of View: Step Up for Biotechnology